Immuno-oncology
News from the FDA/CDC
FDA Approves First Engineered Cell Therapy for a Solid Tumor
This T-cell receptor therapy modifies existing receptors to recognize an array of antigens on the surface of cancer cells.
Feature
Is Immunotherapy Best for Unresectable HCC with Moderate Liver Dysfunction?
A new study compares outcomes following two paths of care for patients with unresectable hepatocellular carcinoma.
Feature
Cancer Drug Shortages Continue in the US, Survey Finds
Not having enough of a significant spectrum of generic chemotherapies and supportive care medications is an ongoing issue, NCCN surveys suggest....
Conference Coverage
MUC-1 vaccine associated with notable overall survival rates in breast cancer
Patients with HER2-negative early breast cancer receive preoperative standard of care neoadjuvant treatment with or without tecemotide, in new...
Conference Coverage
New mRNA Vaccines in Development for Cancer and Infections
Different forms and designations of mRNA vaccines are used, depending on the application and desired effect.
From the Journals
Do Patients Benefit from Cancer Trial Participation?
Researchers conduct a meta-analysis comprising 141 comparisons of an investigational drug and a control treatment, which include immunotherapies...
Conference Coverage
How New ICI Combos Change Bladder Cancer Management
Immune checkpoint inhibitor combinations have restructured treatment guidelines for metastatic urothelial carcinoma.
Latest News
ASCO Releases Vaccination Guidelines for Adults With Cancer
Oncologists may be key in ensuring patients with cancer safely receive vaccinations and avert avoidable infections.
Conference Coverage
Therapeutic HPV16 vaccine clears virus in most patients with CIN
An experimental vaccine delivered by electroporation cleared virus in 78% of women with CIN2/3 by 6 months.
Feature
Extraordinary Patients Inspired Father of Cancer Immunotherapy
Renowned researcher, Dr. Steven A. Rosenberg, describes his path to pioneering the use of immunotherapies in treating cancer.
Feature
TIL for Melanoma: What Are the Costs and Other Challenges to Getting It to Patients?
Doctors are prepared to advocate for insurance coverage of the newly approved therapy on a case-by-case basis.